Delving into the Latest Updates on GS-9911 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

GS 9911, GS9911

Target

DGKA

Mechanism

DGKA inhibitors(diacylglycerol kinase alpha inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Solid tumor

Inactive Indication-

Originator Organization

Gilead Sciences, Inc.

Carna Biosciences, Inc.

Active Organization

Gilead Sciences, Inc.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors.
The primary objectives of this study are to:
* Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors
* Identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended dose for expansion (RDE) of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors

Start Date09 Oct 2023

Sponsor / Collaborator

Gilead Sciences, Inc.

100 Clinical Results associated with GS-9911

Login to view more data

100 Translational Medicine associated with GS-9911

Login to view more data

100 Patents (Medical) associated with GS-9911

Login to view more data

100 Deals associated with GS-9911

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	Phase 1	US	Gilead Sciences, Inc.	09 Oct 2023
Solid tumor	Phase 1	AU	Gilead Sciences, Inc.	09 Oct 2023
Solid tumor	Phase 1	CA	Gilead Sciences, Inc.	09 Oct 2023